FDA Approves Lerodalcibep-liga (LEROCHOL) as Third-Generation PCSK9 Inhibitor for Cholesterol Management
核心洞察
The FDA has approved lerodalcibep-liga (搜索) (LEROCHOL (搜索)) as a novel third-generation PCSK9 inhibitor for reducing LDL cholesterol in adults with hypercholesterolemia (搜索), including heterozygous familial hypercholesterolemia (搜索).
LEROCHOL (搜索) demonstrated sustained LDL-C (搜索) reductions of ≥60% in cardiovascular disease (搜索) patients and ≥50% in heterozygous familial hypercholesterolemia (搜索) patients during clinical trials.
The drug offers enhanced convenience with once-monthly subcutaneous injection and extended room-temperature stability up to three months, addressing barriers that have limited PCSK9 inhibitor adoption.
The U.S. Food and Drug Administration has approved lerodalcibep-liga (搜索) (LEROCHOL (搜索)) injection for subcutaneous use as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C (搜索)) in adults with hypercholesterolemia (搜索), including heterozygous familial hypercholesterolemia (搜索) (HeFH). The approval, announced by LIB Therapeutics (搜索) on December 15, 2025, marks the introduction of a novel third-generation PCSK9 inhibitor designed to address convenience barriers that have limited widespread adoption of this drug class.
Novel Design Addresses Treatment Barriers
LEROCHOL (搜索) is engineered as a small protein-binding PCSK9 inhibitor featuring an 11-kDa polypeptide called adnectin, designed for high-affinity subnanomolar binding to human PCSK9 and fused to human serum albumin to enhance plasma half-life. The drug is administered as a once-monthly, single small-volume subcutaneous injection with extended room-temperature stability up to three months, eliminating refrigeration requirements that distinguish it from all currently approved PCSK9 inhibitors.
"The primary challenge in lipid management today is helping patients achieve and maintain the increasingly stringent LDL-C (搜索) targets in current guidelines," said Dean J. Kereiakes, M.D., Chairman of The Christ Hospital Heart and Vascular Institute and Professor of Medicine at the University of Cincinnati. "While PCSK9 inhibitors as a class deliver powerful cholesterol lowering potential, LEROCHOL (搜索) was designed to address the barriers that have limited their use, including ease of use features like a single small monthly injection, self-administered at home with extended room-temperature stability for home storage and travel."
Clinical Trial Results Support Efficacy
The FDA approval was based on data from the comprehensive global Phase 3 LIBerate Clinical Trial Program, which enrolled over 2,900 patients with cardiovascular disease (搜索), patients without CVD at very high and high risk for CVD, and those with heterozygous and homozygous familial hypercholesterolemia (搜索). Lerodalcibep was administered once monthly for up to 52 weeks in placebo-controlled trials, with over 2,400 patients continuing in the 72-week open-label extension trial.
In clinical trials, LEROCHOL (搜索) demonstrated sustained LDL-C (搜索) reductions of ≥60% in patients with, or at very high or high risk of, cardiovascular disease (搜索) and ≥50% in those with HeFH who have more severe LDL-C elevations. The drug was generally well tolerated across the LIBerate Clinical Trial Program, with no treatment-related serious adverse events reported in the long-term extension studies.
Addressing Unmet Medical Need
Cardiovascular disease (搜索) remains the leading cause of death globally and in the United States, with lower LDL-C (搜索) levels demonstrated to lead to better outcomes. Despite the availability of statins and other lipid-lowering therapies, millions of patients with or at risk of CVD, including those with familial hypercholesterolemia (搜索), fail to achieve updated guideline-recommended LDL-C targets.
Approximately 1 in 200 individuals worldwide have familial hypercholesterolemia (搜索), a genetic condition characterized by severely elevated LDL-C (搜索) levels from birth that requires lifelong management. While PCSK9 inhibitors as a class offer the most effective and safe LDL-C lowering, widespread adoption has been limited by inconvenience and access barriers.
Safety Profile and Adverse Events
The most commonly occurring adverse reactions in clinical trials for primary hyperlipidemia in adults, including HeFH (≥2% of patients treated with LEROCHOL (搜索) and occurring more frequently than with placebo), were nasopharyngitis (15% and 14% versus placebo), local injection site reactions (12% and 5% versus placebo), and peripheral edema (2% and <1% versus placebo).
In HeFH-specific trials, the most common adverse reactions were injection site reactions (18% and 3% versus placebo), nasopharyngitis (13% and 9% versus placebo), diarrhea (3% and 1% versus placebo), nausea (2% and 0% versus placebo), and peripheral edema (2% and <1% versus placebo). The most frequent adverse reaction leading to treatment discontinuation was injection site reactions, occurring in 1% of LEROCHOL (搜索)-treated patients versus 0% in placebo-treated patients.
Commercial Launch and Global Expansion
LEROCHOL (搜索) is expected to be available in the United States as a pre-filled syringe in spring 2026, with an upgraded autoinjector device expected later in the year. LIB Therapeutics (搜索) has committed to working with payers, healthcare providers, and patient advocacy organizations to ensure broad access to LEROCHOL for patients who need it.
The company has also submitted a Marketing Authorization Application to the European Medicines Agency, with anticipated approval in June 2026, and is pursuing additional regulatory submissions in other markets worldwide.
"We founded LIB Therapeutics (搜索) with a mission to bring an effective and more patient-friendly treatment option to the millions of patients who still need additional LDL-C (搜索) reduction in order to achieve the lower targets recommended in recent guidelines," said Evan Stein, M.D., Ph.D., Founder, CEO and Chief Scientific Officer of LIB Therapeutics. "Today's FDA approval validates that mission and the focus of my medical career."